

systemic lupus erythematosus (SLE) · thrombocytopenia · vertigo

► **Frequency not known**

- With oral use Anaemia · anxiety · depressive symptom · fatigue · fever · hearing impairment · influenza like illness · pancreatitis · pancytopenia · rhabdomyolysis · serum sickness-like reaction · smell altered · tinnitus · vasculitis · vision disorders

- With topical use Hypersensitivity

SIDE-EFFECTS, FURTHER INFORMATION

Liver toxicity With oral use; discontinue treatment if liver toxicity develops (including jaundice, cholestasis and hepatitis).

Serious skin reactions With oral use; discontinue treatment in progressive skin rash (including Stevens-Johnson syndrome and toxic epidermal necrolysis).

● **PREGNANCY**

- With topical use Manufacturer advises use only if potential benefit outweighs risk—*animal* studies suggest no adverse effects.
- With oral use Manufacturer advises use only if potential benefit outweighs risk—no information available.

● **BREAST FEEDING**

- With topical use Manufacturer advises avoid—present in milk. Less than 5% of the dose is absorbed after topical application of terbinafine; avoid application to mother's chest.
- With oral use Avoid—present in milk.

● **HEPATIC IMPAIRMENT**

- With oral use Manufacturer advises avoid (risk of increased exposure).

● **RENAL IMPAIRMENT**

Dose adjustments ► With oral use Use half normal dose if estimated glomerular filtration rate less than 50 mL/minute/1.73 m² and no suitable alternative available.

● **MONITORING REQUIREMENTS**

- With oral use Monitor hepatic function before treatment and then periodically after 4–6 weeks of treatment—discontinue if abnormalities in liver function tests.

● **PATIENT AND CARER ADVICE**

- With oral use Manufacturer advises that patients should immediately report any signs or symptoms suggestive of liver dysfunction such as pruritus, unexplained persistent nausea, decreased appetite, anorexia, jaundice, vomiting, fatigue, right upper abdominal pain, dark urine, or pale stools. Patients with these symptoms should discontinue taking terbinafine and the patient's liver function should be immediately evaluated.

● **EXCEPTIONS TO LEGAL CATEGORY**

- With topical use Preparations of terbinafine hydrochloride (maximum 1%) can be sold to the public for use in those over 16 years for external use for the treatment of tinea pedis as a cream in a pack containing maximum 15 g, or for the treatment of tinea pedis and cruris as a cream in a pack containing maximum 15 g, or for the treatment of tinea pedis, cruris, and corporis as a spray in a pack containing maximum 30 mL spray or as a gel in a pack containing maximum 30 g gel.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 9

► **Terbinafine (Non-proprietary)**

Terbinafine (as Terbinafine hydrochloride) 250 mg Terbinafine 250mg tablets | 14 tablet [PoM] £18.11 DT = £1.80 | 28 tablet [PoM] £3.56–£34.93

► **Lamisil** (Novartis Pharmaceuticals UK Ltd)

Terbinafine (as Terbinafine hydrochloride) 250 mg Lamisil 250mg tablets | 14 tablet [PoM] £21.30 DT = £1.80 | 28 tablet [PoM] £41.09

Cream

EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates

► **Terbinafine (Non-proprietary)**

Terbinafine hydrochloride 10 mg per 1 gram Terbinafine 1% cream

| 15 gram [PoM] £3.17 DT = £1.54 | 30 gram [PoM] £6.33 DT = £3.08

► **Lamisil** (GlaxoSmithKline Consumer Healthcare)

Terbinafine hydrochloride 10 mg per 1 gram Lamisil 1% cream | 30 gram [PoM] £8.76 DT = £3.08

ANTISEPTICS AND DISINFECTANTS >

UNDECENOATES

Undecenoic acid with zinc undecenoate

● **INDICATIONS AND DOSE**

Treatment of athletes foot

- TO THE SKIN

- Child: Apply twice daily, continue use for 7 days after lesions have healed

Prevention of athletes foot

- TO THE SKIN

- Child: Apply once daily

- **UNLICENSED USE** *Mycota*[®] licensed for use in children (age range not specified by manufacturer).

- **CAUTIONS** Avoid broken skin · contact with eyes should be avoided · contact with mucous membranes should be avoided

● **SIDE-EFFECTS**

- Rare or very rare Skin irritation

SIDE-EFFECTS, FURTHER INFORMATION Treatment should be discontinued if irritation is severe.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Cream

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances

- **Mycota (zinc undecenoate / undecenoic acid)** (Thornton & Ross Ltd)

Undecenoic acid 50 mg per 1 gram, Zinc undecenoate 200 mg per 1 gram Mycota cream | 25 gram [GSL] £2.01

Powder

EXCIPIENTS: May contain Fragrances

- **Mycota (zinc undecenoate / undecenoic acid)** (Thornton & Ross Ltd)

Undecenoic acid 20 mg per 1 gram, Zinc undecenoate 200 mg per 1 gram Mycota powder | 70 gram [GSL] £3.04

ANTISEPTICS AND DISINFECTANTS > OTHER

Chlorhexidine with nystatin

● **INDICATIONS AND DOSE**

Skin infections due to *Candida* spp.

- TO THE SKIN

- Child: Apply 2–3 times a day, continuing for 7 days after lesions have healed

- **UNLICENSED USE** Licensed for use in children (age range not specified by manufacturer).

- **CAUTIONS** Avoid contact with eyes and mucous membranes

- **SIDE-EFFECTS** Hypersensitivity · skin reactions

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Cream

EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates